THERAPY DOSSIER · th-ad35aa026ad0

ADTM, (R)-(3,5,6-trimethylpyrazinyl) methyl-2-acetoxy-3-(3,4-diacetoxyphenyl) propanoate, a danshensu derivative

Drug · ADTM, a danshensu/tetramethylpyrazine hybrid derivative (antithrombotic/antioxidant).

Evidence & regulatory context

Mechanism: ADTM, a danshensu/tetramethylpyrazine hybrid derivative (antithrombotic/antioxidant).
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29890255 ↗2018Reported benefit

A novel Ca current blocker promotes angiogenesis and cardiac healing after experimental myocardial infarction in mice.

MixedIschaemia-reperfusionCardiacC57BL/6Male12 to 24 mg/kg in mice; 50 to 200 microM in zebrafish; 200…Treatment given after myocardial infarction for 14 days

Model: Experimental myocardial infarction

ADTM at 12 to 24 mg/kg for 14 days significantly reduced myocardial infarct size and increased peri-infarct vessel density, and 24 mg/kg raised serum VEGF (P < 0.05). ADTM rescued chemical-induced vessel loss in zebrafish and increased VEGF in A7r5 cells, and at 200 microM inhibited L-type calcium…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…